18/06/2026 GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis GRI Bio secured FDA Orphan Drug Designation for Tazarotene in Idiopathic Pulmonary Fibrosis (Ref) GRI Bio announced that the US FDA had granted Orphan Drug Designation to Tazarotene (GRI-062; oral RARβ/γ-selective agonist) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The designation marked a significant regulatory milestone and provided a potential pathway to se